Letteratura scientifica selezionata sul tema "Statut juridique des cellules souches"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Statut juridique des cellules souches".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "Statut juridique des cellules souches":
Petit, Élodie. "Éléments de réflexion sur le choix d’un modèle de réglementation pour l’embryon et les cellules souches embryonnaires". Les Cahiers de droit 45, n. 2 (12 aprile 2005): 371–402. http://dx.doi.org/10.7202/043800ar.
Hunyadi, Mark. "La biotechnologie ou l'imagination au pouvoir". Études Tome 413, n. 9 (1 settembre 2010): 187–97. http://dx.doi.org/10.3917/etu.4133.0187.
GAUDEMARD, LYNDA. "Métaphysique et éthique de la reproduction". Dialogue 56, n. 1 (marzo 2017): 1–19. http://dx.doi.org/10.1017/s0012217317000233.
Jmel Boyer, Inès, e Emmanuel García Sánchez. "Le développement embryonnaire pré-gastrulatoire humain : modèles d’avenir et enjeux sociétaux". Biologie Aujourd’hui 214, n. 3-4 (2020): 109–13. http://dx.doi.org/10.1051/jbio/2020012.
Anthony, Boivin, Céline Malesys, Mira Maalouf, Catherine Colin, Olivier Chapet, Claire Rodriguez-Lafrasse e Dominique Ardail. "80: Sensibilisation de cellules souches cancéreuses issues de carcinomes ORL à la radiothérapie après modulation de leur statut redox". Bulletin du Cancer 97, n. 1 (marzo 2010): S67—S68. http://dx.doi.org/10.1016/s0007-4551(15)31173-5.
Boudin, Laurys, Christian Chabannon, Patrick Sfumato, Renaud Sabatier, François Bertucci, Carole Tarpin, Magali Provansal et al. "Expérience de l’institut Paoli-Calmettes concernant la chimiothérapie à haute dose et autogreffe de cellules souches hématopoïétiques pour la prise en charge des cancers mammaires : impact du statut Her2 et BRCA1/2". Bulletin du Cancer 104, n. 4 (aprile 2017): 332–43. http://dx.doi.org/10.1016/j.bulcan.2016.12.007.
Nweke-Okorocha, G. O., H. H. Gunn e B. O. Agaviezor. "Effects of breed and sex on haematological indices of local and improved chickens raised in the South-south region of Nigeria". Nigerian Journal of Animal Production 49, n. 1 (25 febbraio 2022): 10–11. http://dx.doi.org/10.51791/njap.v49i1.3395.
Tesi sul tema "Statut juridique des cellules souches":
Perez, Castiglioni Monica Patricia. "Le statut juridique des cellules souches : de la greffe d’organes à la thérapie cellulaire". Electronic Thesis or Diss., Paris 8, 2021. http://www.theses.fr/2021PA080048.
Stem cells as cellular products for therapeutic purposes (PCT) or as advanced therapy drugs (ITNs) within the framework of regenerative medicine have revolutionized the medicine of the 21st century. Faced with recent discoveries of new stem cells created by researchers (parthenotes, cloned stem cells, iPS cells), other possibilities for regenerative therapy are emerging over time.The law, which has always accompanied the scientific and technical development of cell therapy since the 17th century, must be more present than ever to protect human beings who lend themselves to new treatments or to experimentation. The historical development of this therapeutic revolution allows us to show the importance of legal and ethical reflection for scientific progress.Old questions, such as the status of the prenatal being and the authorization for cryopreservation of autologous tissues or cells, are re-emerging in the face of the presence of supernumerary human embryonic stem cells and the success of regenerative therapy. Teratogenic treatments and episodes of child abuse during pregnancy have destroyed or damaged thousands of unborn children. Recognition of prenatal life is offered in certain circumstances to protect the embryo and fetus before birth
Fournier, Carole. "Le strontium comme inhibiteur de l'adipogenèse et modulateur du statut redox des cellules souches mésenchymateuses". Thesis, Saint-Etienne, 2011. http://www.theses.fr/2011STET004T.
Age-related osteoporosis is associated with both an increased marrow adiposity while bone mass decreased and an increased oxidative stress. Mesenchymal stem cells (MSCs) differentiate into osteoblasts or adipocytes and their capacity of self-renewal and differentiation is influenced by cell redox status. Strontium (Sr) have an anti-fracture effect in vivo however, it doesn’t clearly modulate markers of mature bone cell activities. Starting from this observation, we hypothesized that MSCs could be a cellular target of Sr, and particularly the inhibition of their adipocyte differentiation could reduce the marrow lipotoxicity which is deleterious for the osteoblast survival during aging. Our study showed that Sr-treated mice presented a lower medullary adiposity and a higher trabecular bone volume as compared to control animals. It was demonstrated that Sr rapidly inhibited adipogenesis of multipotent mesenchymal cells (MMCs) C3H10T1/2 by repressing PPARγ2 and droplet lipid formation in a partially ERK-dependant pathway. This mechanism was linked to its proliferative effect since in presence of Sr the higher Cyclin D1 gene expression; the lower was that of PPARγ2. Moreover, Sr prevented the establishment of processes involved in the cell redox status and necessary for the adipocyte maturation such as mitochondrial biogenesis, Rac1 protein accumulation (a NADPH oxidase regulatory subunit) and increase of the antioxidant enzyme expression. Sr also induced intracellular reactive oxygen species (ROS) decrease that could explain its anti-adipogenic action. Indeed, ROS are essential for the CSM commitment toward adipogenesis and they oxidize lipids which could in turn activate PPAR. Taken together, these data showed that Sr by modulating the intracellular ROS production maintained a redox status supporting the MMCs proliferation and preventing adipocyte differentiation. Thus, the antioxidant and anti-adipogenic capacities of future molecules could define new therapeutic approaches for osteoporosis treatment
Laporte, Camille. "Potentiel cytoprotecteur des cellules souches mésenchymateuses sur les îlots exposés à des cytokines pro-inflammatoires ou encapsulés : identification de facteurs pouvant améliorer leur statut oxydatif et inflammatoire". Thesis, Université Grenoble Alpes (ComUE), 2018. http://www.theses.fr/2018GREAS015.
Although, the metabolic results of islets transplantation for patient with type 1 diabetes are now well documented, they are counteracted by the adverse effects of immunosuppressive therapies and the long-term loss in graft functionality.During this thesis, we worked on two complementary approaches offering the perspective of avoiding immunosuppressive treatment while protecting islets from apoptosis and loss of functionality induced by the mechanisms of isolation, culture and transplantation. These two tools are islet immunoisolation in capsules composed of specific biomaterials and islets co-transplantation with mesenchymal stem cells (MSCs) described for their immunomodulatory, proangiogenic and cytoprotective properties.In the european project of bioartificial pancreas BIOCAPAN, we have evaluated in vitro the biocompatibility of several biomaterials and we have highlight a combined effect of the presence of MSCs and tripeptides RGD on the viability and the functionality maintenance of the encapsulated islets. Subsequent in vivo validation of the biocompatibility and the added effect of the BIOCAPAN capsule on diabetic animals will allow the final validation of the capsule to be proposed for clinical trials.We also demonstrated, in an islet co-culture model with MSCs under conventional culture conditions and exposed to pro-inflammatory cytokines, that MSCs regulate the secretory capacity of islets probably via the regulation of heme oxygenase 1 (HO-1) described for its antioxidant and anti-inflammatory properties. The identification of transcription factors regulating HO-1 as well as mediators, allowing communication between the two cell types, are development perspectives.This work underlined the interest, within an immuno-isolation approach, of the reconstitution of a favorable environment within the capsule allowing the preservation of islet physiology thanks to the use of MSCs
Chadli, Loubna. "Contrôles moléculaires du statut de cellule souche kératinocytaire dans l’épiderme interfolliculaire humain adulte : Rôle des facteurs de transcription de la voie du TGF-β1". Thesis, Paris 11, 2012. http://www.theses.fr/2012PA11T055.
Stem cells present within the human interfollicular epidermis, which are defined as keratinocytes stem cells (KSC), ensure the homeostasis and renewal of the tissue throughout the whole individual life. These functions are related to their important self-renewal capacity. My PhD project was focused on the knowledge of the molecular effectors involved in the control of the balance between proliferation and quiescence in KSC. This scientific question was investigated in an in vitro model of KSC which were clonally derived and characterized as holoclones. Holoclones are controlled by mitogenic growth factors and also by antiproliferative signals. One of these regulators is the growth factor TGF β1 which plays an important role in the control of quiescence and cell proliferation within several adult stem cell systems. In the context of growth inhibition by TGF β1, I have studied the role of a downstream gene of the TGF β pathway, the transcription factor Klf4, whose role in adult stem cell biology remains unclear. In fact, Klf4 is mostly described for its involvement in the reprogramming process of somatic cells into iPS cells. The maintenance of holoclone sensitivity to cell growth inhibitors is a critical parameter of KSC normal physiology. Holoclones possess an extensive growth capacity, which is characteristic of KSC. Despite this high proliferation rate, holoclones are still responsive to the antiproliferative effect of TGF β1. These results allowed us to validate the use of holoclone as a relevant model of non-transformed KSC suitable for the characterization of the role of candidate stemness genes in KSC biology, such as Klf4. The holoclone model was exploited to perform a functional genomic approach to investigate the role of Klf4 in KSC. We have developed a shRNA-based gene knock-down method using lentiviral vectors to assess the impact of Klf4 down-modulation on holoclone functional properties. Our results show that Klf4 down modulation controls the expansion of the clonogenic compartment present within holoclone progeny. This gain-of-function, which is maintained at the long term level, leads to an increase in holoclone 3D epidermis reconstruction capacity. A major point of this project was to elucidate the molecular networks controlled by Klf4 in holoclones. Microarray data show that Klf4 regulates the expression of several genes related to pathways involved in the control of stem cell fate. In particular, we identified many transcripts related to TGF β/BMP and Wnt signallings. Interestingly, the majority of the modulated transcripts are involved in the regulation of cell cycle and in keratinocyte differentiation process. All together these results suggest a critical role Klf4 as a stemness censor of the most immature compartment activity. Klf4 is likely to be involved in cell cycle regulation of KSC compartment and in the control of KSC self-renewal process
Drouin, Érika Véronique. "L'utilisation des cellules souches embryonnaires à des fins thérapeutiques". Thèse, 2003. http://hdl.handle.net/1866/2381.
The embryonic stem cells discovery and the immense therapeutic potential glven to them has created big hopes in the world of today. The appearance of new revolutionary therapies to treat sorne of the most serious known diseases are now conceivable. However, the treatment of life to its earliest stage is questionned. The legal status recognized to the foetus and the embryo has, in fact, a direct effect to the research area and industry as weil as to its therapeutic use. Therefore, we have examined and studied the CUITent canadian law with respect to the legal status of the foetus and embryo. Following this study, we have noticed the uncertainty that prevails in Canada concerning the said legal status. Afierwards, we have examined ail the different canadian norms and regulations already established regarding the use of embryonic stem cells for therapeutic ends. We also did the comparaison between those norms and regulations so as to see their differences and similarities. It appears from our analysis that ail the canadian litterature generally treat the subject in the same way and that there have been few changes from 1993 up until now with respect to the forbidden researchs activities in Canada. We also have analysed the foreign law standards and regulations in United States and Great Britain concerning those forbidden researchs activities. We did the exercise of comparing the state of the law in these three countries with different parameters. It emerges from that that Great Britain is the most liberal country, United States being the most conservative and Canada being in between them.
"Mémoire présenté à la Faculté des études supérieures en vue de l'obtention du grade de Maîtrise en droit (L.L.M.) Option recherche"
Bélanger, Véronique. "Évaluation du statut nutritionnel en zinc des enfants poursuivant un protocole de greffe de cellules souches hématopoïétiques". Thèse, 2016. http://hdl.handle.net/1866/18854.
It has been previously documented that plasma zinc levels are lower in children who underwent a hematopoietic stem cell transplant (HSCT). Given the role of zinc in hematopoiesis, immune defense, intestinal integrity and growth, it is likely that zinc deficiency may negatively affect patient outcomes by influencing hematopoiesis recovery, vulnerability to infections, occurrence of diarrhea, inflammatory complications and growth. To date, monitoring of this trace element is not routinely done in children undergoing HSCT at Ste-Justine Hospital. In this prospective study, we assessed plasma zinc levels and zinc intakes in 21 children at seven different time points before and after HSCT. In addition, anthropometric and biochemistry parameters as well as complications were collected at the same time points. Our results showed a prevalence of zinc deficiency (<9.9 μmol/L) of 43%, however no specific time was associated with the occurrence of this deficiency. Gender, age, graft type, primary diagnosis and the use of a nutritional support did not significantly affect the prevalence of this deficiency state. Usual zinc intakes could not explain this impairment while the use of parenteral nutrition did not prevent its occurrence. A poor nutritional status at admission, defined by a low weight-for-age (<25th percentile), could help identifying high-risk patients. This association is strengthened by the positive correlation found between prealbumin and plasma zinc levels. Although an altered zinc status resulted in a longer duration of diarrhea and more stools per day as well as an extended period of mucositis and neutropenia, no significant difference was seen between patients with a normal and an impaired zinc status with regard to these outcomes. This study suggests the relevance of monitoring zinc nutritional status during HCST given the significant proportion of patients with impaired zinc status and the apparent increase in post-HCST complications seen in those patients. Since usual zinc intakes do not explain the alteration of zinc status of our study population, further studies are needed.